PIPELINE

We are developing a cell therapy product candidate pipeline of first-in-class cellular immunotherapies for cancer and autoimmune diseases. Our proprietary portfolio is built on groundbreaking scientific achievements, with a particular focus on CXCR5-driven approaches, to address life-threatening diseases with unmet medical needs and limited treatment options. Our pipeline is further driven by the expansion of indications across cancer and autoimmune diseases.